Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Bio-Gene Technology Ltd. ( (AU:BGT) ) is now available.
Bio-Gene Technology Limited announced that its product, Qcide, has been approved by the Organic Materials Review Institute (OMRI) for listing as a Botanical Insecticide under the USDA National Organic Program. This approval enhances Bio-Gene’s market positioning by allowing Qcide to be used in organic and sustainable pest control markets, expanding its potential customer base. The listing supports Bio-Gene’s strategy of offering environmentally responsible products and opens new commercial opportunities in the growing organic agriculture and eco-label markets.
More about Bio-Gene Technology Ltd.
Bio-Gene Technology Limited is an Australian company focused on developing next-generation insecticides derived from natural sources. The company’s primary product, Qcide, is a natural, non-synthetic essential oil extracted from Eucalyptus cloeziana, aimed at providing sustainable pest control solutions.
Average Trading Volume: 697,304
Technical Sentiment Signal: Hold
Current Market Cap: A$7.93M
For a thorough assessment of BGT stock, go to TipRanks’ Stock Analysis page.